Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all news
12.13.2013

Corey Raines Quoted in Product Liability Law Reporter

The American Association for Justice published an article in its Product Liability Law Reporter on Dec. 10, 2013 titled “Battle Brewing over FDA Generic Drug Labeling Ruling.” The article, written by Courtney L. Davenport, is about the FDA’s proposed changes to generic drug labeling and features quotes from Wexler Wallace associate Corey Raines.

The FDA’s proposed rule would allow generic drugmakers to submit label changes once they learn of safety concerns – not once the brand-name manufacturer has initiated changes.  Corey has written a number of posts for the Wexler Wallace blog regarding this topic; In particular the Supreme Court’s ruling in PLIVA, Inc. v. Mensing in 2011 and how the FDA’s subsequent proposed rulemaking would effectively overturn theMensing decision. In the AAJ article, she is quoted as saying:

“The FDA’s proposed rule is an acknowledgement of the inherent, significant problems that result from the inability of generic drug manufacturers to initiate changes to their labeling. Currently, consumers have no legal remedy should they be injured by a generic drug. In essence, this rule will make all drug manufacturers responsible for their products and protect the legal rights of consumers.”

To read the full article as it appeared in the Product Liability Reporter, click here. To read any of Corey’s articles regarding the Mensing decision, visit the Wexler Wallace Blog here, here and here.

Share

  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP